Clearmind Medicine (CMND) Return on Capital Employed (2023 - 2026)
Clearmind Medicine (CMND) posted quarterly Return on Capital Employed of 73.07% for Q2 2026, up 9360.0% year-over-year from 0.77% in Q2 2025, and up 35.0% quarter-over-quarter from 112.42% in Q1 2026.
Clearmind Medicine (CMND) Return on Capital Employed (2023 - 2026) Analysis & Trends
Clearmind Medicine's Return on Capital Employed history runs 4 years deep, the most recent figure standing at 73.07% for Q2 2026.
- In Q2 2026, Return on Capital Employed rose 9360.0% year-over-year to 73.07%; the TTM figure through Apr 2026 stood at 73.07% (up 9360.0% YoY), while the FY2025 annual figure was 205.07%, up 720.0% from the prior year.
- Return on Capital Employed for Q2 2026 stood at 73.07%, up from 112.42% in the prior quarter.
- The five-year high for Return on Capital Employed was 73.07% in Q2 2026, with the low at 3072.72% in Q4 2023.
- The 4-year median for Return on Capital Employed is 166.67% (2025), against an average of 658.77%.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed soared 292621 bps in 2024, then plunged 253879 bps in 2025.
- Clearmind Medicine's Return on Capital Employed stood at 3072.72% in 2023, then soared by 95 bps to 146.51% in 2024, then tumbled by 1733 bps to 2685.3% in 2025, then soared by 97 bps to 73.07% in 2026.
- Business Quant data shows CMND's Return on Capital Employed at 73.07% in Q2 2026, 112.42% in Q1 2026, and 2685.3% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Clearmind Medicine | 537,435.54 | -13.06 Mn | - | -81.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -73.07% |
| Jan 31, 2026 | -112.42% |
| Oct 31, 2025 | -2,685.30% |
| Jul 31, 2025 | -255.03% |
| Apr 30, 2025 | -166.67% |
| Jan 31, 2025 | -160.02% |
| Oct 31, 2024 | -146.51% |
| Jul 31, 2024 | -212.82% |
| Apr 30, 2024 | -126.97% |
| Jan 31, 2024 | -234.94% |
| Oct 31, 2023 | -3,072.72% |